I asked about the company's publication plan and Leo responded with "which drug?" I said, all of them, but Kevetrin Phase 1 data to start. He deferred to Dr. Menon who gave a very vague answer about how the manuscript has been submitted and it takes time due to the lengthy review process.
Basically, I got the feeling that Dr. Menon is either too busy, too distracted, or having health problems and cannot dedicate the time to put publishing as a priority (or some combo of all three). I also wonder how much experience he has writing manuscripts as lead author (I'm thinking very little) and also with human clinical study data (probably none).
He didn't disclose the journal where the manuscript was submitted, and he did not clarify the time frame for eventual publication, so I can only assume that the paper is in the review process, which I agree can take a considerable amount of time. There's a lot of back and forth with the reviewers and having to respond or make edits tot he paper. Not to mention, I believe a number of investigators at Dana Farber are probably co-authors so I assume it is difficult to track them down to review changes.
People have clambered on about visibility of the company and attracting new investors. I would have thought publishing data is a [relatively] cheap and sure fire way of gaining attention. I would like to see the pre-clinical and mechanism of action data on Kevetrin published (not just as a poster at a conference), as we all as the pre-clinical stuff on Prurisol. I think this is all very noteworthy data that would easily get accepted in a top tier journal.
So, a strategic publication plan is on my holiday wish list for CTIX, along with a VP of Clinical Development, a VP of Regulatory Affairs, a reliable IR firm, and up-listing to Nasdaq (duh!).
AI
Market Data 
Markets 
